In high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), blasts constitutively activate the antiapoptotic transcription factor nuclear factor-jB (NF-jB). Here, we show that this NF-jB activation relies on the constitutive activation of the IjB kinase (IKK) complex, which is formed by the IKKa, IKKb and IKKc/ NF-jB essential modulator (NEMO) subunits. A cellpermeable peptide that mimics the leucine zipper subdomain of IKKc, thus preventing its oligomerization, inhibited the constitutive NF-jB activation and induced apoptotic cell death in a panel of human MDS and AML cell lines (P39, MOLM13, THP1 and MV4-11). Small interfering RNA-mediated knockdown of the p65 NF-jB subunit or the three IKK subunits including IKKc/NEMO also induced apoptotic cell death in P39 cells. Cell death induced by the IKKc/NEMO-antagonistic peptide involved the caspase-independent loss of the mitochondrial transmembrane potential as well as signs of outer mitochondrial membrane permeabilization with the consequent release of cytochrome c, apoptosis-inducing factor and endonuclease G. Primary bone marrow CD34 þ cells from high-risk MDS and AML patients also succumbed to the IKKc/NEMO-antagonistic peptide, but not to a mutated control peptide. Altogether, these data indicate that malignant cells in high-risk MDS and AML cells critically depend on IKKc/NEMO to survive. Moreover, our data delineate a novel procedure for their therapeutic removal, through inhibition of IKKc/NEMO oligomerization.
Introduction
The transcription factor nuclear factor-kB (NF-kB) is involved in oncogenesis by virtue of its capacity to regulate the expression of a plethora of genes that modulate apoptosis and cell survival as well as proliferation, inflammation, tumor metastasis and angiogenesis (Smahi et al., 2002; Karin et al., 2004; Luo et al., 2005) . Different reports demonstrate the intrinsic activation of NF-kB in lymphoid and myeloid malignancies, including preneoplastic conditions such as myelodysplastic syndromes (MDS), underscoring its implication in malignant transformation (Braun et al., 2006a, b) . Targeting intrinsic NF-kB activation, as well as its upstream and downstream regulators, may hence constitute an additional approach to the oncologist's armamentarium.
MDS are clonal stem cell disorders with different characteristics at the early and the late stages of the disease (Dombret et al., 2002; Fenaux, 2005; Lindberg, 2005; Steensma and Bennett, 2006) . Early MDS associate blood cytopenias, which can be explained by an increased apoptotic turnover of hematopoietic stem cells and differentiating myeloid cells in a hypercellular bone marrow (BM). In early MDS, the clonal population that is undergoing apoptosis does not show any signs of NF-kB activation (Braun et al., 2006a) . Latestage MDS, which is coupled to NF-kB activation, is marked by a progressive increase of immature cells and frequent transformation to acute myeloid leukemia (AML), presumably owing to a progressive suppression of programmed cell death and increased clonal proliferation. AML represents a heterogeneous group of clonal stem cell malignancies arising from so-called leukemic stem cells (LSC) (Guzman et al., 2001 (Guzman et al., , 2002 Estrov et al., 2003) . LSC give rise to leukemic myeloid blasts arrested at different (Guzman et al., 2001 ) maturation steps. Several studies have characterized the activation level of NF-kB in the BM of AML patients and more precisely in LSC (Guzman et al., 2001) . Constitutively active NF-kB (mostly p50/p65) has been detected in premalignant and malignant cells derived from patients with high-risk MDS (Braun et al., 2006a) and AML (Guzman et al., 2001) . Targeting NF-kB in these hematopoietic malignancies leads to apoptosis, corroborating the role of NF-kB in the survival and clonal expansion of malignant cells.
The principal NF-kB activation pathway involves the phosphorylation of inhibitor of NF-kB (IkB) at serine residues 32 and 36 by IkB kinase (IKK), which is built up by the IKKa, IKKb and IKKg/NF-kB essential modulator (NEMO) subunits (Ghosh and Karin, 2002) . The IkBs are then polyubiquitinated and degraded by the proteasome, therefore allowing nuclear translocation of the NF-kB dimers and activation of their target genes. IKK can be activated by multiple intra-and extracellular stimuli (Karin et al., 2004) , and the inhibition of IKK by inhibitors of the catalytic IKK subunits IKKa and IKKb can induce apoptosis in MDS and AML cell lines (Baumgartner et al., 2002; Braun et al., 2006a) .
The level of oligomerization of NEMO/IKKg has been suggested to be involved in IKK activation. The minimal oligomerization domain of this protein consists of two coiled-coil subdomains named coiled-coil 2 (CC2) and leucine zipper (LZ) (Agou et al., 2004a) . Cell-permeable peptides corresponding to the CC2 and LZ subdomains that mimic the contact areas between IKKg subunits can prevent the oligomerization of IKKg. In particular, a LZ peptide with an IC 50 in the mM range strongly inhibits the activation of NF-kB induced by external stimuli (Agou et al., 2004b) .
Here, we addressed the questions whether IKKgantagonistic peptides might inhibit the constitutive activation of NF-kB in MDS and AML cells and whether they induce apoptosis in such cells. In addition, we characterized the mechanisms through which IKKgantagonistic peptides kill MDS and AML cells.
Results and discussion
IKKg/NEMO-antagonistic peptide induces apoptosis in MDS/AML cell lines The 'NEMO peptide' is a peptide corresponding to the LZ oligomerization subdomain of IKKg/NEMO (YKADFQAERHAREKLVEKKEYLQEQLEQLQR EFNKL) that has been fused to the polyarginine (R7) plasma membrane-permeable motif (RRRRRRRLKA QA) in the N-terminus. A very similar peptide when fused to the antennapedia cell-permeable sequence (RQ1KIWFQNRRMKWKK) enters cells and inhibits the IKK-dependent NF-kB transactivation (Agou et al., 2004a) . We tested the effect of the NEMO peptide on the myelomonocytic P39 cell line (Figure 1a and b) , which has been derived from the BM of a MDS/AML patient (Nagai et al., 1984) , as well as on the MOLM13 cell line (Figure 1d and e), which has been derived from the peripheral blood of a patient with post-MDS AML (Matsuo et al., 1997) . When P39 or MOLM13 cells were cultured in the presence of NEMO peptide, they readily lost their mitochondrial transmembrane potential (DC m ), as determined with the DC m sensitive fluorochrome 3,3 0 dihexyloxacarbocyanine iodide (DiOC 6 (3)) (Metivier et al., 1998) , and permeabilized their plasma membranes, as determined with the vital dye propidium iodide (PI) (Figure 1a and d) . In addition, P39 cells ( Figure 1c ) and MOLM13 cells (not shown) underwent morphological changes characteristic of apoptosis, in particular nuclear shrinkage (pyknosis), as detected by staining with the chromatin dye Hoechst 33342. As a control, we used a mutated peptide (dubbed here 'control peptide') that carried two Ser-Pro amino-acid substitutions and that does not inhibit the oligomerization of IKKg/NEMO. In contrast to the NEMO peptide, we found that the control peptide had no proapoptotic effect on P39 or MOLM13 cells (Figure 1a and d), nor on any other cell type, including AML cell lines and primary tumor cell derived from patients (see below). As a result, we consider that the control peptide is completely inert, at least as far as its apoptosisinducing potential is concerned.
Similar results were obtained in an additional series of experiments in which P39 or MOLM13 cells were exposed to the NEMO peptide and their apoptotic response was comparatively assessed by staining with fluorescein isothiocyanate (FITC)-labeled annexin V, which binds to phosphatidylserine residues exposed on the plasma membrane. Both cell lines underwent apoptosis upon culture with the NEMO peptide (but not with the control peptide), as indicated by phosphatidylserine exposure and loss of viability (Figure 1b and e). Control experiments performed on the P39 cell line corroborated that the NEMO peptide but not the control peptide inhibited the NF-kB system (as measured by electrophoretic mobility shift assay (EMSA), Figure 2a ). Moreover, P39 cells died when transfected with small interfering RNAs (siRNAs) that target IKKg/NEMO at a rate that is comparable to the cell death induced by knockdown of the catalytic subunits of IKK (IKKa/IKK1 and IKKb/IKK2) or the NF-kB subunit p65 (Figure 2b-d) . This result confirms that these cells rely on the expression/function of IKKg/ NEMO to survive.
Caspase-dependent and -independent mechanisms of cell death induced by the IKKg/NEMO-antagonistic peptide The addition of the pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VADfmk) fully blocked nuclear pyknosis induced by the NEMO peptide (Figure 1c ), delayed the phosphatidylserine exposure and loss of viability ( Figure 1b and e), yet had no or little effect on the DC m loss triggered by the NEMO peptide ( Figure 1a and d), suggesting that the mitochondrial alterations occur in a caspaseindependent manner, upstream of the caspase-dependent phosphatidylserine exposure and cell death. To gain some mechanistic insights into the apoptotic pathway stimulated by the IKKg/NEMO-antagonistic peptide, we exposed P39 cells to a short pulse (6 h) with the NEMO peptide (or the control peptide) and then determined the activation of caspase-3 by immunofluorescence staining with an antibody that recognizes only proteolytically mature, cleaved caspase-3. In the same conditions, we determined the mitochondrial release of cytochrome c, apoptosis-inducing factor (AIF) and EndoG, as indicated by their redistribution from a cytoplasmic punctate to a diffuse immunofluorescencestaining pattern. NEMO peptide (but not the control peptide) stimulated caspase activation and a marked release of mitochondrial death effectors ( Figure 3 ). In addition, the NEMO peptide reduced the expression of two NF-kB target gene products, namely Bcl-X L and endogenous inhibitor of mitochondrial membrane permeabilization and cellular inhibitor of apoptosis protein 2 (c-IAP2) (Figure 4 ), an endogenous inhibitor of caspases. These data support the idea that the NEMO peptide stimulates the mitochondrial pathway of apoptosis in P39 MDS/AML cells. Altogether, it appears that the IKKg/NEMO-antagonistic peptide can stimulate canonical mitochondrial apoptosis with caspase activation.
IKKg/NEMO-antagonistic peptide induces apoptosis in AML cell lines AML is frequently characterized by a constitutive activation of the NF-kB system. The NEMO peptide, used at a dose that inhibits the constitutive NF-kB activation (Figure 5a ), killed a variety of AML cell lines (THP1, an acute monocytic leukemia: Figure 5b and c; MV4-11, an acute monocytic leukemia: Figure 5d and e), and no such cytotoxic effect was observed for the control peptide. Again, the effect of the 
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DiOC6 ( IKKg/NEMO-antagonistic peptide induces apoptosis in primary tumor cells from high-risk MDS and AML patients As pointed out in the Introduction, CD34
þ BM cells from normal individuals or those from low-risk MDS patients do not exhibit NF-kB activation, whereas CD34 þ cells from high-risk MDS or AML patients rely on constitutively active NF-kB to survive. If this activation depended on the classical IKKg/NEMOdependent pathway, then the NEMO peptide should kill high-risk MDS and AML CD34 þ cells. As compared to the control peptide (Figure 6 ) or absence of any peptide (not shown), the IKKg/NEMO-antagonistic peptide did induce signs of apoptosis (including DC m loss and plasma membrane permeabilization) in a fraction of cells from high-risk MDS patients as well as in AML patients. In contrast, there was no selective cell death induction in CD34 þ cells from healthy controls and the elevated spontaneous apoptosis of CD34 þ cells from low-risk MDS patients was not enhanced by the NEMO peptide ( Figure 6 ). In high-risk MDS treated with the NEMO peptide, the p65 subunit of NF-kB disappeared from the nucleus, whereas cytochrome c was released from mitochondria and caspase-3 was activated ( Figure 7 ). These data indicate that interruption of constitutive IKKg/NEMO-dependent NF-kB activation leads to activation of the mitochondrial cell death pathway.
Concluding remarks
The results presented in this paper lead to two major conclusions. First, it appears clear that constitutive NF-kB activation, as it occurs in MDS and AML cell lines, relies on the constitutive activation of the IKKg/ NEMO of the IKK complex. This finding corroborates and extends previous results showing that inhibition of the catalytic subunits of IKK, for instance with BAY 11-7082, can abolish the MDS/AML-associated constitutive NF-kB activation and hence trigger mitochondrial apoptosis through a pathway that is lethal even when caspases are inhibited (Braun et al., 2006a b) . As shown here, the NEMO peptide that abolished heterodimerization of IKKg/NEMO exerts its lethal effect in a truly specific manner, through the inhibition of IKKg/ NEMO, and hence can be used as a probe to assess accurately the pathophysiological implication of IKKg/ NEMO in the system. The addition of the NEMO peptide to primary cells derived from the BM with highrisk MDS and AML causes NF-kB inhibition and mitochondrial cell death, hence confirming the critical role of IKKg/NEMO-dependent NF-kB activation in the pathogenesis of MDS/AML. IKKg/NEMO may have additional functions that probably are not related to IKK oligomerization or NF-kB activation (Gloire et al., 2006; Nakamori et al., 2006) . Thus, the use of agents that specifically inhibit IKKg/NEMO oligomerization (but not IKKg/NEMO as such) may have comparatively lower side effects than would the inhibition of the IKKg/NEMO protein expression.
Second, our data suggest that IKKg/NEMO may be used as a potential therapeutic target, as previously suggested by Agou et al. (2004b) . Past knowledge in the design of pharmacological agents suggested that it would be impossible to target protein-protein interaction and that drug designs should focus on the inhibition of catalytic sites. However, recent developments suggest that such interaction domains may constitute a prospective target for small molecule inhibitors (Arkin and Wells, 2004; Dev, 2004; Oltersdorf et al., 2005) . The data contained in this paper suggest that it might be possible to generate IKKg/NEMO-specific inhibitors acting at a reasonable degree of specificity to induce apoptosis in hematopoietic tumor cells.
Patients, materials and methods
NEMO peptides
Control peptide (R7-NLM-LZ ProPro) with no inhibitory effect was designed as follows: Acetyl.RRRRRRRLKAQA DIYKADFQAERHAREKLVEKKEYPQEQLEQPQREFNKL. amide NEMO peptide (R7-NLM-LZ w.t.) with an inhibitory effect was designed as follows: Acetyl.RRRRRRRLKAQADI YKADFQAERHAREKLVEKKEYLQEQLEQLQREFNKL. amide. These peptides were synthesized at l'Unite´de Chimie Organique (Pasteur Institute, Paris), as described (Agou et al., 2004b) , and peptide purity (>98%) was controlled by mass spectrometry.
Cells and culture conditions
The high-risk MDS cell lines P39/Tsugane (Nagai et al., 1984) was a kind gift by Dr Yoshida Takeda, Japan. The MDS cell line MOLM13 and the AML cell lines MV4-11 and THP1 were purchased from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Germany. All cell lines were cultured in Roswell Park Memorial Institute 1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 IU/ml penicillin and 100 g/ml streptomycin as described (Hassan et al., 1999) . BM cells were isolated and processed as follows: after density gradient (Ficoll-Paque Plus, Amersham Biosciences, Sunnyvale, CA, USA) separation of CD34 þ , cells were isolated from the BM mononuclear cells (BMMNC) compartment by positive selection with the MiniMacs system (Miltenyi Biotec, Bergish Gladbach, Germany). Cells were maintained in Iscove's modified Dulbecco's medium (Gibco) supplemented with 10% heat-inactivated FCS.
Transfection and knockdown of IKK1, IKK2, NEMO and p65 by siRNA Cells were transfected with the Nucleofactor system (Amaxa, Cologne, Germany) using siRNAs specific for Emerin and NF-kB, IKK1, IKK2, NEMO and p65 (Upstate, Lake Placid, NY, USA, Smartpool). As a control, we targeted the nuclear envelope protein Emerin, whose knockdown does not induce any known phenotype. Cells were used 48 h after transfection.
Assessment of apoptosis
Cells (10 5 ) from all MDS and AML cell lines or patient cells were resuspended in 1 ml of culture medium and incubated in the presence or absence of 15 mM NEMO inhibitory peptide and control peptide, 50 mM z-VAD-fmk, for 48 h. Apoptotic cells were detected by flow cytometry analysis using a FACScan (Becton Dickinson, Mountain View, CA, USA) as described previously (Castedo et al., 2002; Zamzami and Kroemer, 2004) . Cells were stained with PI (5 mg/ml, Sigma, St Louis, MO, USA) for 15 min and concomitantly with 40 nM fluorochrome DiOC 6 (3) (Molecular Probes, Eugene, OR, USA) for 15 min at 371C, or with annexin V-FITC (Becton Dickinson) for 15 min at 41C for the determination of the mitochondrial transmembrane potential (DC m ) and phosphatidylserine exposure (Castedo et al., 1996; Metivier et al., 1998) .
Nuclear protein extraction and electrophoretic mobility shift assay Nuclear extracts were obtained from all cell lines. Cells were cultured for 24 h in the presence or absence of 15 mM of NEMO peptide. Cells were harvested and washed twice with ice-cold phosphate-buffered saline (PBS). Cell pellets were then lysed in hypotonic lysis buffer (5 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid-potassium hydroxide (HEPES), 1 mM MgCl 2 , 0.2 mM ethylenediaminetetraacetic acid (EDTA), 0.5 M NaCl, 25% glycerol, pH 7.0). After incubation on ice for 10 min, nuclei were separated from the cytosolic extracts by centrifugation (13 000 g, 5 min at 41C). The nuclear pellets were resuspended in hypertonic extraction buffer (10 mM HEPES, 1.5 mM MgCl 2 and 10 mM KCl, pH 7.9) for 1-2 h at 41C under agitation. After centrifugation (13 000 g, 10min at 41C), supernatants containing nuclear proteins were removed and stored at À701C. Nuclear extracts were examined for NF-kBbinding activity by EMSA, using a non-radioactive EMSA kit (Panomics, Fremont, CA, USA).
Immunofluorescence P39 or patient cells (10 5 ) were allowed to adhere on polylysin-L coverslips (Sigma) and fixed in PBS containing 4% paraformaldehyde at room temperature. Cells were then permeabilized either with 0.05% Triton X-100 (Boehringer, Mannheim, Germany) or 0.1% sodium dodecyl sulfate (SDS) for 10 min, washed in PBS and stained with p65 (rabbit polyclonal Ab, Santa Cruz Biotechnology, Santa Cruz, CA, USA), cytochrome c (mouse monoclonal Ab, BD Pharmingen, Heidelberg, Germany), endonuclease G (rabbit polyclonal Ab, Pro-Science, Woburn, MA, USA), AIF (rabbit polyclonal Ab, Chemicon, Temecula, CA, USA), Hsp60 (mouse monoclonal Ab or rabbit polyclonal Ab, from Sigma and Stressgen, San Diego, CA, USA, respectively) and revealed either with a goat anti-rabbit and goat anti-mouse IgG coupled with Alexa 568 (red) or Alexa 488 (green) fluorochromes (Molecular Probes). DNA of cells was counterstained with Hoechst 33324 (Molecular Probes) allowing the discernment of chromatin condensation (Castedo et al., 2002) .
Immunoblots
Cellular lysates (40 mg protein/lane) were subjected to SDSpolyacrylamide gel electrophoresis, transfered on nitrocellulose membranes and immunochemical detection using antibodies specific for Bcl-X L (S18, Santa Cruz), c-IAP2 (H85, Santa Cruz), IKK1 (M280, Santa Cruz), IKK2 (C20, Santa Cruz), NEMO (FL-419, Santa Cruz), p65 (C20, Santa Cruz) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Chemicon).
Patients
A total of 10 MDS and five AML patients were included in our study, after their informed consent, in a procedure approved by the Institutional Review Board. MDS patients were previously untreated, except for supportive care. The diagnosis of MDS and AML was based on peripheral blood counts, cytology of peripheral blood and BM according to the WHO classification (Vardiman et al., 2002) and conventional cytogenetic analysis. These data permitted to evaluate the individual International Prognostic Scoring System score for each patient (Greenberg et al., 1997) . BM aspirates were obtained after informed consent into syringes containing media supplemented with EDTA. The BMMNC fraction was isolated by density gradient centrifugation using FicollPaque PLUS (Amersham Biosciences).
Abbreviations AIF, apoptosis-inducing factor; AML, acute myeloid leukemia; BMMNC, bone marrow mononuclear cells; Casp-3a, activated caspase-3; Cyt c, cytochrome c; DCm, mitochondrial transmembrane potential; DAPI, 4 0 ,6-diaminidino-2-phenylindole; DiOC6(3), 3,3 0 dihexyloxacarbocyanine iodide; EndoG, endonuclease G; FACS, fluorescence-activated cell sorter; FISH, fluorescent in situ hybridization; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Hsp60, heatshock protein 60; IkB, inhibitor of NF-kB; IKK, IkB kinase; MDS, myelodysplastic syndrome; MMP, mitochondrial membrane permeabilization; NEMO, NF-kB essential modulator; NF-kB, nuclear factor kB; PI, propidium iodide; z-VAD.fmk, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone.
